Takeda's Qdenga dengue vaccine approved in Europe

9 December 2022
dengue_mosquito_large

Succeeding where others have failed, Japanese pharma major Takeda ‘s (TYO: 4502) Qdenga (dengue tetravalent vaccine [live, attenuated]; TAK-003) has been granted regulatory approval by the European Commission.

The vaccine is cleared for the prevention of dengue disease in individuals from four years of age in the European Union (EU). Qdenga should be used in accordance with official recommendations.

The approval follows the positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in October 2022, and adds to regulatory approval in Indonesia in August this year. It is also being evaluated by the US Food and Drug Administration under its Priority Review scheme.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight